Polarix: A Phase 3 Study of Polatuzumab Vedotin (Pola) Plus R-CHP Versus R-Chop in Patients (Pts) With Untreated DLBCL
Hematological Oncology - United Kingdom
doi 10.1002/hon.36_2629
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2019
Authors
Publisher
Wiley